Private equity investment in MedTech has grown significantly over the past decade. PE funds are attracted by the sector's resilience, recurring revenue characteristics, and demographic tailwinds. But MedTech deals carry unique commercial risks that standard financial due diligence does not capture.
What Financial Models Miss
Financial due diligence tells you what happened. Revenue grew at 8% per year. Margins expanded by 200 basis points. Customer retention was 95%.
What it does not tell you is whether these trends will continue. Is the revenue growth driven by market expansion or market share gains? Are the margins sustainable as competitors enter? Is the customer retention high because the product is sticky, or because customers have not yet found alternatives?
These are commercial questions. They require sector expertise, customer insight, and competitive analysis to answer.
MedTech-Specific Risks
MedTech acquisitions carry several commercial risks that are unique to the sector.
Regulatory risk is the most obvious. MDR and IVDR are forcing product portfolio rationalization across Europe. A target company's revenue may include products that will be discontinued or require significant reinvestment to maintain compliance.
Reimbursement risk is equally important. Healthcare payers are increasingly scrutinizing the value of medical technologies. Products that are reimbursed today may face pricing pressure or coverage restrictions in the future.
Procurement concentration is a third risk. Many MedTech companies derive a significant share of revenue from a small number of hospital groups or GPOs. Understanding the depth and durability of these relationships is critical.
What Good Commercial Due Diligence Looks Like
Effective commercial due diligence for MedTech deals combines three elements.
First, market analysis. Understanding market size, growth drivers, competitive dynamics, and regulatory trends provides the context for evaluating the target's position and potential.
Second, customer validation. Structured interviews with customers, distributors, and key opinion leaders provide ground-truth validation of the target's commercial claims. This is where you learn whether customer relationships are genuine or fragile.
Third, value creation planning. Good CDD does not just identify risks. It identifies opportunities and provides a roadmap for post-acquisition value creation. Where can the commercial engine be improved? What growth levers are underutilized? How can the acquirer's capabilities accelerate the target's commercial trajectory?
The Cost of Getting It Wrong
The cost of inadequate commercial due diligence in MedTech is measured in destroyed value. Overpaying for unsustainable revenue, underestimating integration complexity, or missing regulatory risks can turn a promising acquisition into a value trap.
Investing in specialized commercial due diligence is not an expense. It is insurance against the most common causes of MedTech deal failure.